Observational studyHaematologica2023

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.

Alexis Talbot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.